NEW YORK, Jan. 6 (GenomeWeb News) - Xoma of Berkeley, Calif., and Diversa of San Diego have signed a licensing and development agreement, the companies said today.
Diversa will license Xoma's antibody expression technology as well as obtain an option for an antibody production license. In return, Xoma will receive a license fee and potential future milestone and royalty payments.
Xoma and Diversa also plan to co-develop antibodies for autoimmune-related diseases. Xoma will provide Diversa with research funding, and Diversa will be entitled to milestone and royalty payments on any drugs developed under the agreement.